Aptevo's Q2 2026 Update: Compelling AML Data, New CSO, and Niowave's Equity Stake
APVO is trading near its 52-week low of $3.35 (0.0% above the low).
Summary
Aptevo's Q2 2026 results featured strong mipletamig AML data, the appointment of a new CSO, and disclosure of Niowave's 7.9% equity investment.
Key Events · Earnings and Guidance · APVO
-
Mipletamig AML Data Strong
Updated RAINIER trial data showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable frontline AML patients, with 55% achieving MRD-negative status.
-
New Chief Scientific Officer
Mary J. Janatpour, Ph.D. has been appointed as SVP and CSO, bringing over 25 years of oncology R&D leadership.
-
Niowave Equity Investment
Niowave made an at-the-market equity investment at closing, representing an initial 7.9% ownership position, with potential to build up to 19.99%.
-
Cash Position
Cash and cash equivalents totaled $9.8 million as of June 30, 2026, with $0.6 million raised under SEPAs during Q2.
Analysis · APVO · Life Sciences
The Q2 update from Aptevo carries several material developments: mipletamig's frontline AML data are compelling, with an 87% clinical benefit rate and 81% remission rate; a new Chief Scientific Officer has been appointed; and Niowave has confirmed a 7.9% equity stake in the company. While the cash position of $9.8 million remains tight, the clinical momentum and strategic collaboration strengthen the investment thesis.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1427 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $3.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $3.35 to $48.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.